Afatinib is approved in the major ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) regions of the USA, EU and Japan for the treatment of patients with non-small cell lung cancer harbouring distinct EGFR activating mutations [35–37]. Here, EGFR is linked to non-small cell lung carcinoma.